Valuation: Indivior Pharmaceuticals, Inc.

Capitalization 3.96B 3.37B 3.11B 2.93B 5.44B 369B 5.53B 36.44B 14.28B 177B 14.87B 14.56B 631B P/E ratio 2026 *
12x
P/E ratio 2027 * 10.2x
Enterprise value 3.75B 3.18B 2.94B 2.77B 5.14B 349B 5.23B 34.45B 13.5B 168B 14.06B 13.77B 597B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.91x
Free-Float
96.11%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5d. change 1-year change 3-years change Capi.($)
+1.56%+5.27%+49.52%-20.18% 3.96B
-0.11%-5.36%+23.01%+142.78% 810B
-1.73%-2.81%+52.39%+41.57% 575B
+0.27%-1.61%+21.73%+29.66% 369B
-0.59%+0.48%+23.57%+13.94% 324B
+0.65%-2.33%+44.57%+24.97% 311B
-2.07%-5.89%+51.01%+0.39% 291B
-0.78%-3.10%+30.18%+34.27% 289B
+0.34%-1.75%+23.62%+40.84% 188B
-0.87%-2.49%+32.10%+65.67% 173B
Average -0.47%-1.53%+35.17%+37.39% 370.04B
Weighted average by Cap. -0.54%-1.29%+33.60%+57.51%

Financials

2026 *2027 *
Net sales 1.16B 985M 909M 857M 1.59B 108B 1.62B 10.66B 4.18B 51.91B 4.35B 4.26B 185B 1.22B 1.04B 957M 902M 1.67B 114B 1.7B 11.22B 4.4B 54.65B 4.58B 4.48B 194B
Net income 353M 300M 277M 261M 485M 32.88B 493M 3.25B 1.27B 15.82B 1.33B 1.3B 56.25B 413M 350M 324M 305M 566M 38.39B 576M 3.79B 1.49B 18.47B 1.55B 1.52B 65.67B
Net Debt -216M -183M -169M -160M -296M -20.09B -301M -1.98B -778M -9.66B -810M -793M -34.36B -412M -350M -323M -305M -566M -38.38B -575M -3.79B -1.49B -18.47B -1.55B -1.52B -65.66B
Logo Indivior Pharmaceuticals, Inc.
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
32.52USD
Average target price
46.86USD
Spread / Average Target
+44.09%

Quarterly revenue - Rate of surprise